AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15657666
Drug: PTP injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTP injection into intersphincteric space and internal anal sphincter without guidance by endoanal ultrasound (Group B, n = 40)
Trial: 18359127
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment (0.03% or 0.1%)
Trial: 9761513
Drug: RenaGel (calcium-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RenaGel (calcium- and aluminium-free phosphate binder), starting doses of one, two, or three 500-mg capsules three times per day with meals for 8 weeks.
Trial: 9761513
Drug: RenaGel treatment
RxNorm normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RenaGel treatment
Trial: 7800969
Drug: OM-85 BV
RxNorm normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-85 BV (oral administration)
Trial: 7800969
Drug: OM-85 BV
RxNorm normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-85 BV (injection)
Trial: 3364402
Drug: UV-A (320-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-A (320-400 nm) doses of 17.8 +/- 1.9 J/cm2 to the anterior side and 21.0 +/- 3.3 J/cm2 to the posterior side, with UV-B (280-320 nm) doses equivalent to 10% of UV-A doses.
Trial: 28532870
Drug: High repetitive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High repetitive, high dosage medical exercise therapy (MET), n=16
Trial: 28532870
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage exercise therapy (ET), n=17
Trial: 25466662
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements (600 kcal, 20 g/d protein) and intensive rehabilitation program
Trial: 25466662
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements and rehabilitation program
Trial: 23315099
Drug: Palliative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative chemotherapy with CA 19-9, CEA, CRP, LDH, and bilirubin levels assessed before treatment and during treatment (for CA 19-9 only)
Trial: 23315099
Drug: Pre-treatment CA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment CA 19-9 levels
Trial: 23315099
Drug: Pre-treatment LDH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment LDH levels
Trial: 23315099
Drug: Pre-treatment CEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment CEA levels
Trial: 23315099
Drug: CA 19-9
RxNorm normalized name: CA-19-9 antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 19-9 decline of ≥25% during the first two chemotherapy cycles
Trial: 19744201
Drug: Chin bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin bone augmentation
Trial: 17094382
Drug: Sequential anthracycline-docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential anthracycline-docetaxel regimen
Trial: 17094382
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with anthracyclines
Trial: 15087630
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg preoperatively
Trial: 3135737
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (timing before or after 4 hours of AMI onset)
Trial: 3135737
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with patent arteries 90 minutes after therapy initiation
Trial: 24469138
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen inhalation sedation
Trial: 24469138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nitrous oxide/oxygen inhalation sedation)
Trial: 22311406
Drug: Feitai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feitai Capsule (1.2 g/capsule, 4 capsules, 3 times a day for 3 weeks, followed by 1 week off, continued for at least 3 more cycles, totaling 12 weeks)
Trial: 15960643
Drug: 0.3 ml.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml.kg(‐1) bupivacaine 0.25% plus 1 microg.kg(‐1) clonidine
Trial: 12580705
Drug: Premarin (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin (conjugated equine estrogen) 0.625 mg/d
Trial: 12580705
Drug: Premarin (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin (conjugated equine estrogen) 1.25 mg/d
Trial: 14674906
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal
Trial: 312366
Drug: Methylprednisolone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (500 mg added to each liter of cardioplegic solution)
Trial: 12006932
Drug: HspE7 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HspE7 (500 microg monthly for 3 months)
Trial: 29481992
Drug: Silicate-based wound
RxNorm normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicate-based wound dressing (DermFactor®) combined with conventional dressing therapy
Trial: 29481992
Drug: Conventional dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dressing therapy
Trial: 20370447
Drug: Unfractioned Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractioned Heparin (UFH)
Trial: 18597921
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRHa)
Trial: 16634346
Drug: Weekly re-evaluation
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly re-evaluation
Trial: 11054359
Drug: Vancomycin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1,000 mg IV, 12 hours before procedure)
Trial: 11054359
Drug: Cefazolin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1,000 mg IV, 3 hours before procedure)
Trial: 8844478
Drug: 0.3 MIU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 MIU IFN, administered twice per week for 24 weeks
Trial: 8844478
Drug: 1 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 MIU IFN, administered twice per week for 24 weeks
Trial: 8844478
Drug: 3 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 MIU IFN, administered twice per week for 24 weeks
Trial: 21414131
Drug: Titanium-13Zirconium (TiZr)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium-13Zirconium (TiZr) implants
Trial: 21414131
Drug: Titanium Grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium Grade IV implants
Trial: 20205166
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 629 to 1835 mg/day
Trial: 20205166
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 648 mg/day (boys)
Trial: 20205166
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 666 mg/day (girls)
Trial: 20205166
Drug: Calcium absorption
RxNorm normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium absorption and bone turnover rates measured using double-stable calcium isotope kinetic analysis
Trial: 20205166
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 1100 mg/day (boys)
Trial: 20205166
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 970 mg/day (girls)
Trial: 17912118
Drug: Poly(L‐lactide‐co‐glycolide) osteofixation
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly(L‐lactide‐co‐glycolide) osteofixation
Trial: 16047154
Drug: Verum (homeopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum (homeopathic treatment) for 6 weeks
Trial: 16047154
Drug: Long-term follow-up
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term follow-up after treatment
Trial: 12452075
Drug: Midazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05 mg/kg) with atropine (0.5 mg)
Trial: 12452075
Drug: Phenobarbital sodium
RxNorm normalized name: Phenobarbital Sodium
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital sodium (2 mg/kg) with atropine
Trial: 2266671
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with glucose
Trial: 2266671
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen of insulin with glucose and albuterol
Trial: 17716826
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) 40,000 U once weekly, starting 7-10 days before radiotherapy
Trial: 12040280
Drug: Combined chemoradiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemoradiotherapy (induction chemotherapy with cisplatin, etoposide, and vinblastine followed by radiotherapy)
Trial: 1962593
Drug: Droloxifene (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene (new antiestrogenic drug)
Trial: 1962593
Drug: Droloxifene (film-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene (film-coated tablet, tablet, and standard solution)
Trial: 6759056
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tiaprofenic acid daily for 1 week
Trial: 21336631
Drug: RelyX Unicem
RxNorm normalized name: Hippeastrum puniceum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RelyX Unicem combined with Gluma Desensitizer (RXU‐G)
Trial: 21336631
Drug: G‐Cem combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Cem combined with Gluma Desensitizer (GCM‐G)
Trial: 21336631
Drug: Panavia21 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panavia21 combined with Gluma Desensitizer (PAN‐G)
Trial: 19233485
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 100 microg once daily, n=166
Trial: 15178656
Drug: 800 micro
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micro g of moistened (2 ml of saline) or dry vaginal misoprostol
Trial: 11965505
Drug: Fenfluramine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (60 mg) once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Trial: 11965505
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Trial: 9781722
Drug: Surfactant (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (30 mg/kg) administered by intrabronchial instillation
Trial: 8162664
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg four times a day)
Trial: 362821
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (Tegretol)
Trial: 362821
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (Neurotol)
Trial: 362821
Drug: Experimental preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental preparations C and D
Trial: 31100038
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg (NIVO3)
Trial: 31100038
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus Ipilimumab 1 mg/kg (NIVO3+IPI1)
Trial: 31100038
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg (NIVO1+IPI3)
Trial: 26995376
Drug: Exenatide once‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide once‐weekly 2 mg
Trial: 17711927
Drug: BW-ADAPTED-T3T4 (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW-ADAPTED-T3T4 (combination of T3 and T4 at a ratio of 1:10)
Trial: 10546333
Drug: Oral exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral exposure to one of the shapes for 90 seconds prior to visual stimuli testing (Experiment 1)
Trial: 7481021
Drug: Propofol (sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (sleep doses and N2O)
Trial: 7481021
Drug: Propofol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (10 mg/kg/h intravenous perfusion)
Trial: 7481021
Drug: Dehydrobenzylperidol (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydrobenzylperidol (90 micrograms/kg) i.m. followed by sleep doses of propofol
Trial: 1980654
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 600 mg/day
Trial: 25621791
Drug: Clonidine (α2‐adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (α2‐adrenergic agonist)
Trial: 8848515
Drug: Scopolamine (muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (muscarinic antagonist)
Trial: 15190052
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamins and minerals (200 mg Mg and 30 mg Zn + 200 mg vitamin C and 150 mg vitamin E)
Trial: 15190052
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E (200 mg vitamin C and 150 mg vitamin E)
Trial: 15190052
Drug: Mg and
RxNorm normalized name: Vraylar 1.5mg and 3mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg and Zn (200 mg Mg and 30 mg Zn)
Trial: 12200215
Drug: Extended-release divalproex
RxNorm normalized name: divalproex sodium Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release divalproex (qd)
Trial: 7831492
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of a stroking procedure
Trial: 7831492
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of stroking procedure and multisensory hammock
Trial: 2477338
Drug: Potassium hydrochloride
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium hydrochloride 1 g twice daily
Trial: 2477338
Drug: Potassium hydrochloride
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium hydrochloride 1 g and magnesium hydroxide 500 mg twice daily
Trial: 334435
Drug: Hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 50 mg daily
Trial: 334435
Drug: Metolazone, 5
RxNorm normalized name: Metolazone, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metolazone, 5 mg daily
Trial: 26848624
Drug: High hs-CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hs-CRP levels (≥ 13.1 mg/L)
Trial: 26848624
Drug: Low hs-CRP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hs-CRP levels (< 13.1 mg/L)
Trial: 22925817
Drug: 600 μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μg of rectal misoprostol
Trial: 22925817
Drug: 20 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 intravenous units of oxytocin
Trial: 20371660
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg/d for 8 weeks)
Trial: 20371660
Drug: Niaspan (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaspan (2000 mg/d for 16 weeks)
Trial: 17439513
Drug: Phloroglucinol/trimethylphloroglucinol (62.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol/trimethylphloroglucinol (62.2 mg P + 80 mg TMP) two pills three times daily for 7 days
Trial: 16270644
Drug: Certoparin (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certoparin (3000 anti-Xa IU, subcutaneously, once-daily)
Trial: 16270644
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5000 IU, subcutaneously, three-times daily)
Trial: 23563560
Drug: Chicken collagen
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken collagen hydrolysate (CCH) 2.9 g/d
Trial: 18317438
Drug: Ritonavir-boosted Atazanavir
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted Atazanavir (300/100 mg)
Trial: 12649101
Drug: GM-CSF mouthwash
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF mouthwash 150 micro g/day
Trial: 10874052
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 2 g/kg
Trial: 7936832
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg birth weight at 12-18 h of age and a second dose 12 h later)
Trial: 29500968
Drug: Hypoenergetic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoenergetic diet high in ALA (3.4 g/d)
Trial: 29500968
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet low in ALA (0.9 g/d)
Trial: 24190696
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (150 mg daily recommended dose, administered in three 50 mg doses across the day and evening)
Trial: 23038965
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin (60 mg/m2 per administration) and continuous infusion of cytarabine during the second course
Trial: 23038965
Drug: High-dose HAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HAM protocol as a second induction course
Trial: 23038965
Drug: High-dose anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anthracycline antibiotics
Trial: 21265466
Drug: Co‐Ir‐vell tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co‐Ir‐vell tablets (test formulation)
Trial: 18541232
Drug: Phytoestrogen genistein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoestrogen genistein (54 mg/day)
Trial: 8619364
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 25 micrograms/kg/day, n = 5
Trial: 8619364
Drug: High-dose IGF-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IGF-I 60 micrograms/kg b.i.d., n = 5
Trial: 8619364
Drug: Low-dose IGF-I
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IGF-I 15 micrograms/kg b.i.d., n = 6
Trial: 8619364
Drug: High-dose IGF-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IGF-I
Trial: 8619364
Drug: Low-dose IGF-I
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IGF-I
Trial: 2248030
Drug: Tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid 600 mg daily for 7 days (monotherapy in 53.2% of cases)
Trial: 2248030
Drug: Tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid 600 mg daily for 7 days (in association with antibiotics in 46.8% of cases)
Trial: 7362419
Drug: Single-dose prediction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose prediction
Trial: 30794429
Drug: Dairy snack
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy snack (Greek yogurt, 198.9 g, 171 kcal, 0 g fat, 17 g protein)
Trial: 30794429
Drug: Nondairy snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondairy snack (mini sandwich-type cookies, 37.5 g, 175 kcal, 7.5 g fat, 1.3 g protein)